Autopsy report · NCT04925557

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

“Lack of recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 1 year 9 months before it stopped.
• 8 participants enrolled.
• Results were posted on the registry 1 year 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

State University of New York at Buffalo

Sponsor type

University, hospital or other

Conditions

Secondary-progressive Multiple Sclerosis

Interventions

Mayzent; Ocrevus

Participants

8

Sites

1

Countries

United States

Trials that died the same way

• Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation
  “lacking recruitment” (96% match in meaning)
• A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass
  “Inadequate recruitment” (93% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.